This report aims to provide a comprehensive study of the global market for biobanking. It provides a detailed description of the different types of biobanks (disease-oriented/clinical based and population-based) worldwide. The biobanking market is segmented based on their application as basic/scientific research and clinical research/therapeutics. Each application segments’ historical and projected market revenues are provided in the report. The global market for biobanking is also segmented based on sample type (as biofluids, tissue, stem cells, DNA/RNA and others) and ownership types (government agencies/public sector providers, academic institutes/universities, non-profit organizations and private organizations). The market revenue for each geographical segment, including North America, Europe, Asia-Pacific and Rest of the World (ROW), have also been provided in the report.
For an in-depth understanding of the market, profiles of market participants are also part of this report. This report also discusses driving and restraining factors and key trends in the biobanking market.
This research covers biobanks dealing with basic science and clinical research. Forensic science, paternity testing, cryopreservation facilities or screening disease testing for newborns and fertility clinics dealing with ovum, sperm and embryo biobanks are not covered in this report. Transplantation and graft-related biobanks dealing with heart valves, cornea and cartilage/tendon are also not covered. Tissue banks for orthopedic, spine, dental, maxillofacial surgery and stem cells biobank for regenerative medicine are also not covered in this report.
Report Includes
- 22 data tables and 29 additional tables
- An up-to-date review and analysis of the global markets for biobanking technologies
- Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the upcoming market potential for biobanking technologies, and areas of focus to forecast this market into various segments and sub-segments
- In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for biobanking products
- Evaluation and forecast the overall market size for biobanks, forecasted growth trends, and corresponding market share analysis by sample type, application, ownership type, and region
- Identification of novel biobanking products and promising new technologies still in the development and testing stage and assess the probability that they will be commercialized successfully in the next five years
- Review of emerging companies and the leading competitors in the prevailing biobanking industry
- Insight into recent patent activities on biobanking techniques, R&D activities, clinical trials under process, and selected list of biobanking studies
- Descriptive company profiles of the major global players, including Agilent Technologies Inc., AstraZeneca plc, Bruker Corp., Hamilton Co., Merck KGaA, Qiagen N.V., and Thermo Fisher Scientific Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of Report
- Methodology and Information Sources
- What's New in This Report?
- Geographic Breakdown
- Analyst's Credentials
Chapter 2 Summary and Highlights
- Key Highlights
Chapter 3 Market and Technology Background
- Biobank Overview
- The Process of Biobanking
- Classification of Biobanks
- Disease-Oriented/Clinical Based Biobanks
- Population-Based Biobanks
- Applications of Biobanks
- Users of Biobanks
- Biobanking Costs
Chapter 4 Current Biobanks Worldwide
- Overview
- Leading Biobanks in North America
- All of Us Research Program
- National Cancer Institute (NCI)
- The National Heart, Lung and Blood Institute (NHLBI) Biologic Specimen and Data Repository
- Kaiser Permanente Research Bank
- The University of Mississippi Medical Center (UMMC)
- The AIDS and Cancer Specimen Resource (ACSR)
- National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository
- BioMe Biobank
- Canadian Partnership for Tomorrow Project (CanPath)
- Leading Infrastructure That Supports Biobanking in North America
- Leading Biobanks in Europe
- The U.K. Biobank
- Biobank Graz
- The International Agency for Research on Cancer (IARC) Biobank
- Danish National Biobank
- FinnGen
- Estonian Biobank
- deCODE Genetics
- Leading Infrastructure that Supports Biobanking in Europe
- BBMRI-ERIC
- EuroBioBank Network
- RD-Connect
- Leading Biobanks in the Asia-Pacific Region
- Biobank Japan
- Victorian Cancer Biobank
- China Kadoorie Biobank
- Shanghai Zhangjiang Biobank
- Leading Infrastructure that Supports Biobanking in the Asia-Pacific Region
- Leading Biobanks in the Rest of World
- The Qatar Biobank
Chapter 5 Analysis of Market Opportunities
- Market Drivers
- Increasing Public Funding in Biobank Projects
- Increasing Applications in Drug Discovery and Development
- Increasing Pharmaceutical and Biotech R&D Spending
- Developments in Analytical Technologies and Assay Methods
- Growing Focus on Mainstream Precision Medicine and Rise of Genomic Medicine/Clinical Genomics
- Biobanking Technique Advancements
- Growing Private Biobanking
- Market Restraints
- Legal and Ethical Challenges
- Sustainability
- Lack of Standardization/Harmonization
- Insufficient Awareness About Biobanking Activities
- SWOT Analysis of Global Biobanking Industry
- Impact of COVID-19
Chapter 6 Market Breakdown by Sample Type
- Overview
- Biofluids
- Tissues
- Stem Cells
- DNA/RNA
- Others
- Market Size and Forecast
- Market Analysis
Chapter 7 Market Breakdown by Application
- Overview
- Biobanking Applications
- Basic/Scientific Research
- Clinical Research/Therapeutics
Chapter 8 Market Breakdown by Region
- Global Market for Biobanking by Region
- North American Market for Biobanking
- Market Analysis
- Market Revenue by Application
- Market Revenue by Country
- European Market for Biobanking
- Market Analysis
- Market Revenue by Application
- Market Revenue by Country
- Asia-Pacific Market for Biobanking
- Market Analysis
- Market Revenue by Application
- Market Revenue by Country
- Rest of the World Market for Biobanking
- Market Analysis
- Market Revenue by Application
- Market Revenue by Sub-region
Chapter 9 Market Breakdown by Ownership Type
- Overview
- Government Agencies/Public Sector Providers
- Academic Institutes/Universities
- Nonprofit Organizations
- Private Organizations
- Market Size and Forecast
- Market Analysis
Chapter 10 Patent Review/New Developments
- Patent Review
- New Developments
Chapter 11 Company Profiles
- AGILENT TECHNOLOGIES INC.
- AMGEN, INC.
- ASTRAZENECA PLC
- AVANTOR INC.
- AZENTA LIFE SCIENCES
- BIOKRYO GMBH
- BRUKER CORP.
- CENTOGENE N.V.
- HAMILTON CO.
- INDIVUMED GMBH
- MERCK KGAA
- QIAGEN N.V.
- TECAN GROUP LTD.
- THERMO FISHER SCIENTIFIC INC.
Chapter 12 Appendix: Acronyms
List of Tables
Summary Table : Global Market for Biobanking, by Ownership Type, Through 2026
Table 1 : Selected Cancer-Specific Biobanks
Table 2 : Selected Population-Based Biobanks
Table 3 : Types of Biobanks Listed on BBMRI-ERIC Database
Table 4 : Number of Studies That Obtained/Used Biospecimens in Clinical Trials, by Funder Type
Table 5 : Leading Global Biobanks/Projects
Table 6 : Selected National Cancer Institute Biobanking Infrastructure
Table 7 : Selected Biobanks in North America
Table 8 : Selected Infrastructure that Supports Biobanking in the U.S.
Table 9 : Selected Biobanks Based in the European Region
Table 10 : BBMRI Services
Table 11 : BBMRI Projects Launched in 2020
Table 12 : Biobanks and Standalone Collection Centers Associated with BBMRI-ERIC
Table 13 : Share of Composite Funding Methods for Biobanks in BBMRI Countries
Table 14 : Selected Biobanks Based in the Asia-Pacific Region
Table 15 : Selected Infrastructure that Supports Biobanking in Asia-Pacific Countries
Table 16 : Genomics Platforms and Applications
Table 17 : Selected Biobanks Focused on Genome Based Research Projects
Table 18 : Selected International Infrastructures/Organizations Supporting the Development of Harmonized Platforms for Biobanks
Table 19 : Selected Large Biobanks Contributing to COVID-19 Research
Table 20 : Global Market for Biobanking, by Sample Type, Through 2026
Table 21 : Oncology Studies Utilizing Tissue Samples
Table 22 : Types of Biomarkers Based on Their Applications
Table 23 : Biomarkers: Drug Development
Table 24 : Applications of Biobank in Cancer Treatment
Table 25 : Global Market for Biobanking, by Application, Through 2026
Table 26 : Clinical Trials Initiated between 2015 and 2021, by Condition
Table 27 : Global Market for Biobanking, by Region, Through 2026
Table 28 : North American of Biobanking Studies, by Funder Type
Table 29 : North American Market for Biobanking, by Application, Through 2026
Table 30 : North American Market for Biobanking, by Country, Through 2026
Table 31 : Selected Biospecimen Based Scientific Initiatives in Europe
Table 32 : European Market for Biobanking, by Application, Through 2026
Table 33 : European Market for Biobanking, by Country, Through 2026
Table 34 : Demographic and Healthcare Statistics for Selected European Countries
Table 35 : Asia-Pacific Market for Biobanking, by Application, Through 2026
Table 36 : Asia-Pacific Market for Biobanking, by Country, Through 2026
Table 37 : RoW Market for Biobanking, by Application, Through 2026
Table 38 : RoW Market for Biobanking, by Sub-region, Through 2026
Table 39 : Selected Government-Owned Biobanks
Table 40 : Selected Academic Institutes/University Owned Biobanks
Table 41 : Selected Nonprofit Organization-Owned Biobanks
Table 42 : Selected Private Biobank Organizations
Table 43 : Global Market for Biobanking, by Ownership Type, Through 2026
Table 44 : Patents Issued on Biobanking Techniques, 2015-2021
Table 45 : Selected Biobanking Studies, 2018-2021
Table 46 : Clinical Trials Initiated between 2015 and 2021 Involving Biobanks, by Therapeutic Area
Table 47 : Hamilton: Automated Sample Management Solutions
Table 48 : Qiagen: Biobanking Portfolio
Table 49 : Thermo Fisher Scientific: Biobanking Solutions
Table 50 : Acronyms Used in the Global Biobanking Industry
List of Figures
Summary Figure A : Global Market for Biobanking, by Ownership Type, 2019-2026
Summary Figure B : Global Market Shares of Biobanking, by Ownership Type, 2020
Figure 1 : Some Common Aims of Biobanks
Figure 2 : Biobank Sample/Data Types
Figure 3 : Flow of Biospecimens and Data Through the Biobanking Infrastructure
Figure 4 : Number of Clinical Trials Using Biospecimens, 2014-2021
Figure 5 : Places that Create/Use Biobanks
Figure 6 : Distribution of Operating Costs for Academic Biobanks
Figure 7 : Genetic Data Release Timeline, the U.K. Biobank
Figure 8 : Share of FinnGen Expenditure for the First Three Years of the Study, 2020
Figure 9 : Publications Referencing Biobanking, 2011-2021
Figure 10 : Drug Development Cost Statistics and Trends
Figure 11 : Share of Biobanks Collaboration on BBMRI-ERIC Database, by Type
Figure 12 : SWOT Analysis of Global Market for Biobanking
Figure 13 : Global Market for Biobanking, by Sample Type, 2019-2026
Figure 14 : Global Market Shares of Biobanking, by Sample Type, 2020
Figure 15 : Biospecimens Paving the Way for Personalized Theory
Figure 16 : Global Market for Biobanking, by Application, 2019-2026
Figure 17 : Global Market Shares of Biobanking, by Application, 2020
Figure 18 : Global Market for Biobanking, by Region, 2019-2026
Figure 19 : Global Market Shares of Biobanking, by Region, 2020
Figure 20 : North American Market for Biobanking, by Application, 2019-2026
Figure 21 : North American Market for Biobanking, by Country, 2019-2026
Figure 22 : European Market for Biobanking, by Application, 2019-2026
Figure 23 : European Market for Biobanking, by Country, 2019-2026
Figure 24 : Top Three Areas of Expertise of Germany Biobanking Ecosystem
Figure 25 : Top Three Areas of Expertise of the U.K. Biobanking Ecosystem
Figure 26 : Top Three Areas of Expertise of the Netherlands Biobanking Ecosystem
Figure 27 : Health Expenditures per Capita for Selected European Countries, 2015-2019
Figure 28 : Asia-Pacific Market for Biobanking, by Application, 2019-2026
Figure 29 : Asia-Pacific Market for Biobanking, by Country, 2019-2026
Figure 30 : Health Expenditures per Capita for Selected Asia-Pacific Countries, 2015-2019
Figure 31 : RoW Market for Biobanking, by Application, 2019-2026
Figure 32 : RoW Market for Biobanking, by Sub-region, 2019-2026
Figure 33 : Global Market for Biobanking, by Ownership Type, 2019-2026
Figure 34 : Global Market Shares of Biobanking, by Ownership Type, 2020
Figure 35 : Clinical Trials on Biobanking, 2015-2021
Figure 36 : Agilent: Annual Revenue, 2018-2020
Figure 37 : Agilent: Revenue Share, by Segment, 2020
Figure 38 : Amgen: Annual Revenue, 2018-2020
Figure 39 : AstraZeneca: Annual Revenue, 2018-2020
Figure 40 : Avantor: Annual Revenue, 2018-2020
Figure 41 : Azenta Life Sciences: Annual Revenue, 2018-2020
Figure 42 : Bruker: Annual Revenue, 2018-2020
Figure 43 : Bruker: Revenue Share, by Segment, 2020
Figure 44 : Centogene: Annual Revenue, 2018-2020
Figure 45 : Centogene: Revenue Share, by Segment, 2020
Figure 46 : Merck: Annual Revenue, 2018-2020
Figure 47 : Qiagen: Annual Revenue, 2018-2020
Figure 48 : Tecan: Annual Revenue, 2018-2020
Figure 49 : Thermo Fisher Scientific: Annual Revenue, 2018-2020
Figure 50 : Thermo Fisher Scientific: Revenue Share, by Segment, 2020
Executive Summary
Biobanks, also known as biorepositories and biolibraries, collect, process, store and distribute human bio-specimens and associated data. The large-scale collection of biological samples with well-annotated clinical and pathological data is critical to research studies. Biobanks are critical resource for researchers to access the required sample and corresponding health information for their research studies. The samples and associated data are used for a range of purposes including genetic and translational research, drug discovery and development, disease-specific biomarker identification and diagnostics studies. Analytical information and insights gained from the biospecimen database can be translated into actionable results for physicians, patients, and life sciences companies; biobanks are critical biomedical databases and research resources. They are vital to the development of novel diagnostics and drugs and for closing the gap between available clinical information and genetic studies.
Given the growing demand for well-annotated, high-quality biospecimens and omics-rich data sets for therapeutic and diagnostic development programs, there has been significant growth in the number of biobanks since 2000. It is estimated that over 1 billion samples are stored in over 1,000 biobanks around the world. The growth can be attributed to increasing demand for bio-banked samples in the area of genomics, metagenomics, proteomics, personalized medicine, disease biology and public health. Increasing funding from private and governmental organizations for biobanks, increasing genomic research activities and increasing investment in R&D activities by various healthcare companies are the other key factors driving the growth in the biobanking market.
Biobanks have become vital to improving population health by making medicine more effective and customized. Demand for biobanking solutions that protect sample integrity and security, and facilitate easy sample access, quick sample retrieval and dispatch times, has also been increasing at a significant rate in the last decade.
Companies Mentioned
- Agilent Technologies Inc.
- Amgen, Inc.
- Astrazeneca plc
- Avantor Inc.
- Azenta Life Sciences
- Biokryo GmbH
- Bruker Corp.
- Centogene N.V.
- Hamilton Co.
- Indivumed GmbH
- Merck Kgaa
- Qiagen N.V.
- Tecan Group Ltd.
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | January 2022 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 61.1 Billion |
| Forecasted Market Value ( USD | $ 76.2 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
